Pharmaceuticals

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

Psyence BioMed is building a pharmaceutical powerhouse by controlling its supply chain, a strategic move that could redefine the future of psychedelic medicine.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.

The tech firm is launching a new transparent, scenario-based AI to de-risk the multi-billion dollar drug development pipeline. But can it succeed?

The biopharma firm's new dividend policy reflects strong 2025 results and a dual strategy of rewarding shareholders while funding M&A and expansion.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

A new study reveals prior authorization policies cause critical delays for heart failure drugs, disproportionately harming vulnerable groups and raising safety concerns.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.

As automation demand soars, ATS Corp. will meet investors to outline its strategy for navigating market shifts and capitalizing on life sciences growth.

Following a major investment, Trialbee appoints a seasoned leader to its board, signaling a push for dominance in AI-driven clinical trial recruitment.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.

In the quest to drug the 'undruggable,' Erasca consolidates worldwide control of its promising pan-RAS inhibitor, setting the stage for a global showdown.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.